Richard C. White, PhD

Richard C. White, PhD

Dr White brings to Spero more than 40 years experience in Infectious Disease drug discovery and development. Much of his career was spent working for major pharmaceutical companies in positions of increasing responsibility at Lepetit, Glaxo, Lederle and finally at Bristol Myers Squibb, where was Vice President of Infectious Disease Drug Discovery for 12 years. In 1997 he transitioned to biotech joining what was then Versicor. He became CSO and Versicor merged with Biosearch Italia to become Vicuron, which was sold to Pfizer in 2005. Since then he has served as an advisor to multiple biotech and pharmaceutical companies. Currently he serves as Chairman of F2G, an Antifungal company in the UK, and is also Chairman of the SAB of Cempra Pharmaceuticals in NC. He has been actively involved in the discovery and development of a total seven currently marketed antibiotics and antivirals. Dr White was originally trained as a microbial biochemist at the University of Oxford in the UK.